Provided by Tiger Fintech (Singapore) Pte. Ltd.

IGC Pharma

0.2837
-0.0015-0.53%
Post-market: 0.2830-0.0007-0.25%19:55 EDT
Volume:70.27K
Turnover:19.72K
Market Cap:22.61M
PE:-2.34
High:0.2920
Open:0.2920
Low:0.2710
Close:0.2852
Loading ...

IGC Pharma Expands Phase 2 Alzheimer's Trial Site

MT Newswires Live
·
08 Apr

IGC Pharma expands CALMA trial with addition of Butler Hospital Program

TIPRANKS
·
08 Apr

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

ACCESS Newswire
·
08 Apr

IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy

MT Newswires Live
·
20 Mar

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

ACCESS Newswire
·
20 Mar

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

ACCESS Newswire
·
10 Mar

IGC Pharma Price Target Maintained With a $3.50/Share by Alliance Global Partners

Dow Jones
·
07 Mar

IGC Pharma develops AI-driven model to improve diagnosis of Alzheimer’s

TIPRANKS
·
04 Mar

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

ACCESS Newswire
·
04 Mar

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
24 Feb

IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’

TipRanks
·
21 Feb

IGC Pharma Q3 Revenue USD 257 Thousand

THOMSON REUTERS
·
18 Feb

IGC Pharma Reports Third Quarter Fiscal 2025 Results

ACCESS Newswire
·
18 Feb

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

ACCESS Newswire
·
11 Feb

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

ACCESS Newswire
·
28 Jan

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

ACCESS Newswire
·
21 Jan

UPDATE 1-IGC trims global corn crop forecast, US estimate cut

Reuters
·
16 Jan

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

ACCESSWIRE
·
13 Jan

IGC Pharma names IGC-AD1 Phase 2 clinical trial ‘CALMA’

TIPRANKS
·
08 Jan

IGC Pharma Inc: Goal of Completing Enrollment and Calma Trial in Second Half of 2025

THOMSON REUTERS
·
08 Jan